Novotech CRO Partners Skin Research Institute
Novotech, an Asia-Pacific CRO, has further strengthened its presence in the region through a Partnership with the Skin Research Institute of Singapore (SRIS). With this partnership, the two groups will be working together to promote combined capabilities in skin research clinical trials.
The Partnership formalizes a long-standing working relationship between the two.
SRIS was established as a collaboration between Agency for Science, Technology and Research (A*STAR), National Healthcare Group (NHG) and Nanyang Technological University (NTU) to conduct high impact, inter-disciplinary skin research that would translate into improved health outcomes and quality of life.
Novotech now has over 20 significant Partnerships with some of the leading medical institutions in the region. The Partnership Program is designed to bring access to investigators, KOLs, and up to 4 million patients for its international biotech clients.
Novotech CEO Dr John Moller said the Partnership with SRIS will support the increasing demand from biotech clients for skin disorder studies in the Asia-Pacific region.
For more information go to https://novotech-cro.com/
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.
